Iron dysregulation represents a fundamental pathological feature of neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This page provides a comprehensive examination of iron metabolism in the brain, including import mechanisms, cellular transport, storage systems, and the relationship between iron dyshomeostasis and neuronal death pathways such as ferroptosis.
```mermaid
flowchart TD
subgraph I["ron_IntakeIron Intake and Transport"]
A["Dietary Iron<br/>Fe2+/Fe3+"] --> B["Duodenal<br/>Enterocytes"]
B --> C["Ferroportin<br/>Export"]
C --> D["Transferrin<br/>Binding"]
D --> E["Cellular<br/>Uptake"]
end
subgraph B["rain_IronBrain Iron Regulation"]
F["Blood-Brain<br/>Barrier -> GFerritin<br/>Storage"]
G --> H["Neuronal Iron<br/>Import"]
H --> I["Mitochondrial<br/>Iron"]
I --> J["Iron-Sulfur<br/>Cluster Biogenesis"]
end
subgraph T["oxicityIron-Induced Toxicity"]
K["Iron Overload"] --> L["ROS Generation<br/>Fenton Reaction"]
L --> M["Lipid<br/>Peroxidation"]
L --> N["DNA<br/>Damage"]
M --> O["Mitochondrial<br/>Dysfunction"]
N --> P["Ferroptosis"]
O --> Q["Apoptotic<br/>Cell Death"]
end
C -->|"Via transferrin"| F
E -->|"Via DMT1"| H
Iron dysregulation represents a fundamental pathological feature of neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This page provides a comprehensive examination of iron metabolism in the brain, including import mechanisms, cellular transport, storage systems, and the relationship between iron dyshomeostasis and neuronal death pathways such as ferroptosis.
| Protein/Gene | Function | Disease Association |
|--------------|----------|---------------------|
| Ferritin | Iron storage | Elevated in AD substantia nigra |
| Ferroportin | Iron export | Mutations cause neurodegeneration |
| Transferrin | Iron transport | Reduced in CSF of PD patients |
| DMT1 | Divalent metal transporter | Increased in AD brain |
| Iron-Sulfur Cluster | Mitochondrial cofactor | Impaired in PD |
| Feature | Alzheimer's Disease | Parkinson's Disease | Huntington's Disease | ALS | NBIA |
|---------|---------------------|---------------------|---------------------|-----|------|
| Primary Iron Accumulation Region | Hippocampus, basal forebrain | Substantia nigra pars compacta | Striatum, cortex | Motor cortex, spinal cord | Globus pallidus |
| Iron Species | Ferrous iron (Fe²⁺) in neurons | Fe²⁺ in dopaminergic neurons | Mutant huntingtin affects iron handling | Iron in motor neurons | Iron accumulation in brain iron |
| Key Proteins | Amyloid-beta chelates iron, ferritin changes | DMT1, ferroportin dysregulation | Altered iron regulatory proteins | Altered transferrin | WIP1, PLA2G6 mutations |
| Mechanism | Aβ-Fe complexes promote ROS | Iron catalyzes dopamine oxidation | Iron promotes mutant HTT aggregation | Iron in oxidative stress | Lipid peroxidation |
| Imaging Marker | Increased T2 signal in hippocampus | Increased R2 in SNc | Elevated iron in striatum | Motor cortex iron | Iron on MRI |
| Therapeutic Target | Iron chelators (deferoxamine, clioquinol) | Iron chelators, neuroprotective | Iron modulation | Iron chelation | Iron chelation |
The brain obtains iron primarily through two main pathways:
Transferrin-Mediated Import: Circulating iron bound to transferrin (TF) enters the brain via transferrin receptor 1 (TFR1) expressed on brain microvascular endothelial cells (BMVECs) of the blood-brain barrier (BBB)[@fahrner2020]. The iron-transferrin complex is internalized through receptor-mediated endocytosis, and iron is released into the endothelial cell cytoplasm via acidified endosomes. Divalent metal transporter 1 (DMT1) then transports non-transferrin-bound iron (NTBI) across the [BBB](/entities/blood-brain-barrier) into the brain interstitial space.
Non-Transferrin-Bound Iron (NTBI): In conditions of iron overload or when transferrin saturation is high, NTBI can enter the brain through alternative mechanisms. The ZIP14 and ZIP8 transporters have been implicated in NTBI uptake by astrocytes and neurons[@fahrner2020].
Ferroportin (FPN): The sole known iron exporter in mammalian cells, ferroportin exports iron from neurons, astrocytes, and oligodendrocytes into the extracellular space[@de2008]. Hepcidin (HAMP) regulates ferroportin by binding to it and causing its internalization and degradation. In the brain, hepcidin is expressed by astrocytes and [microglia](/cell-types/microglia-neuroinflammation), creating a regulatory axis that controls neuronal iron efflux.
Divalent Metal Transporter 1 (DMT1): DMT1 transports Fe²⁺ across endosomal membranes following transferrin-mediated uptake, and also mediates iron import across the plasma membrane in certain cell types. Four isoforms exist, with different N-terminal extensions and C-terminal regulatory elements affecting subcellular localization and iron transport kinetics[@muckenthaler2008].
Ferritin: The primary iron storage protein, ferritin consists of 24 subunits forming a shell that can store up to 4,500 iron atoms. Ferritin light chain (FTL) and heavy chain (FTH) subunits have different iron oxidation properties—with FTH exhibiting ferroxidase activity essential for safe iron mineralization. In neurons, ferritin upregulation is a protective response to iron overload[@ward2020].
Iron Regulatory Proteins (IRP1/IRP2): Post-transcriptional regulation of iron metabolism genes occurs through iron regulatory proteins (IRP1 and IRP2) that bind to iron response elements (IREs) in the 5' or 3' untranslated regions of mRNAs[@krusche2021]. This regulatory system controls expression of TFR1, DMT1, ferritin, and ferroportin based on cellular iron status.
Iron accumulation in Alzheimer's disease occurs in several compartments:
Amyloid Plaques: Iron colocalizes with [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaques in the brains of AD patients[@rathore2022]. The Aβ protein can bind iron through its histidine residues at positions 6, 13, and 14, facilitating iron-mediated Aβ aggregation and toxicity. Iron-Aβ interactions promote the formation of toxic soluble iron-Aβ complexes that generate reactive oxygen species.
Neurofibrillary Tangles (NFTs): Iron accumulates in neurons containing hyperphosphorylated tau protein forming NFTs[@rathore2022]. Iron can directly promote tau phosphorylation through activation of various kinases, including [CDK5](/genes/cdk5) and GSK3β, while tau pathology disrupts neuronal iron export by affecting ferroportin localization.
Regional Distribution: Iron accumulates in the [hippocampus](/brain-regions/hippocampus), basal forebrain, and cortical regions—areas vulnerable to AD pathology. The iron accumulation pattern follows the progression of neurofibrillary tangle pathology (Braak stages), suggesting a relationship between tau pathology and iron dysregulation.
Mechanisms: Iron contributes to AD pathogenesis through:
Iron accumulation in Parkinson's disease is particularly striking in the substantia nigra pars compacta (SNc), where dopaminergic neurons are selectively vulnerable[@dexter2019].
Substantia Nigra: The SNc shows the most dramatic iron increase in PD, with iron levels 2-3 times higher than age-matched controls. Iron accumulates in neuromelanin-containing dopaminergic neurons and in glial cells. The pattern of iron accumulation corresponds to the ventral tier of the SNc, which is most vulnerable to neurodegeneration.
Neuromelanin: This pigment, produced by oxidation of dopamine, has high affinity for iron and can form complexes that both sequester iron and generate toxic species. Neuromelanin acts as a "double-edged sword"—protecting neurons by binding iron under normal conditions but releasing iron during degeneration to promote oxidative damage[@dexter2019].
Mechanisms:
Iron dysregulation in ALS affects both motor neurons and supporting glial cells.
Motor [Neurons](/entities/neurons): Iron accumulates in spinal cord motor neurons of ALS patients, with elevated ferritin expression observed in affected neurons. Mutations in genes linked to ALS (SOD1, [C9orf72](/entities/c9orf72), TARDBP, FUS) affect iron homeostasis[@cai2022].
[Astrocytes](/entities/astrocytes): Astrocytes show altered iron metabolism in ALS, with decreased ferroportin expression potentially contributing to iron accumulation in motor neurons.
Iron-Sulfur Cluster Biogenesis: Several ALS-linked proteins (SOD1, ISCU, NFU1) are involved in iron-sulfur cluster assembly, and their dysfunction disrupts cellular iron homeostasis.
Iron accumulation occurs in the striatum and [cortex](/brain-regions/cortex) in HD, brain regions most affected by the disease.
Mechanisms:
Iron accumulation in the olivary nucleus, putamen, and cerebellum characterizes MSA, contributing to oligodendrocyte dysfunction and neurodegeneration.
The Fenton reaction catalyzes the conversion of hydrogen peroxide (H₂O₂) to hydroxyl radical (•OH), one of the most reactive species in biology:
Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻
The hydroxyl radical attacks lipids (lipid peroxidation), proteins (protein oxidation), and DNA (DNA damage), causing widespread cellular damage. In neurons, which have high metabolic demand and relatively low antioxidant capacity compared to other cell types, Fenton chemistry is particularly damaging[@gao2021].
Iron accumulation impairs mitochondrial function through multiple mechanisms:
Iron promotes aggregation of disease-specific proteins:
Ferroptosis is an iron-dependent, non-apoptotic cell death pathway characterized by:
Iron activates microglia and promotes neuroinflammation:
Deferoxamine (DFO): The classic iron chelator, primarily used for systemic iron overload. Limited BBB penetration restricts its utility for brain iron. Intranasal and subcutaneous delivery routes are being explored[@devos2020].
Deferasirox (DFX): Oral iron chelator with better brain penetration than deferoxamine. Shows promise in preclinical PD and AD models[@devos2020].
Deferiprone (DFP): Small molecule chelator that can cross the BBB. Currently in clinical trials for PD and AD[@devos2020].
Clioquinol: 8-hydroxyquinoline that mobilizes brain iron. Showed cognitive benefit in a Phase II AD trial[@devos2020].
M30 and HLA20: Novel iron chelators with neuroprotective properties, combining iron chelation with monoamine oxidase inhibition.
Feral and Ferroportin Modulators: Compounds that promote iron export through ferroportin without causing systemic iron deficiency.
GPX4 Activators: Compounds that enhance ferroptosis resistance by supporting lipid repair mechanisms.
Vitamin E and CoQ10: Lipid-soluble antioxidants that protect against iron-induced lipid peroxidation.
N-acetylcysteine (NAC): Precursor to glutathione, supports antioxidant defenses.
Recent research has identified a critical pathway linking microglial complement receptor 3 (CR3) to neuronal ferroptosis in Parkinson's disease. Studies using rotenone-induced PD models demonstrate that microglial CR3 promotes neuron ferroptosis through NOX2-mediated iron deposition[@microgliaironpd2024]. This finding establishes a direct mechanistic link between neuroinflammation and iron-dependent cell death in PD, suggesting that targeting the CR3-NOX2 axis may represent a novel therapeutic strategy.
The discovery that loss of WIPI4 (WD repeat domain, phosphoinositide interacting protein 4) causes neurodegeneration through autophagy-independent ferroptosis represents a paradigm shift in our understanding of iron-dependent cell death[@wipi4neurodegeneration2024]. WIPI4 mutations cause beta-propeller protein-associated neurodegeneration (BPAN), characterized by brain iron accumulation. This work demonstrates that ferroptosis can occur independently of classical autophagy pathways, with implications for other NBIA (Neurodegeneration with Brain Iron Accumulation) disorders.
A comprehensive 2024 review examines iron homeostasis changes during brain aging and their relationship to ferroptosis pathways[@ironhomeostasisaging2024]. The aging brain shows progressive iron accumulation, particularly in regions vulnerable to neurodegeneration. This review highlights how age-related iron dysregulation creates a permissive environment for ferroptotic cell death and discusses potential interventions to maintain iron balance during aging.
New insights into the intersection of iron accumulation, neutral lipid metabolism, and motor impairment have emerged from 2024 research[@ironmotorimpairment2024]. This work demonstrates how iron-induced lipid peroxidation contributes to motor dysfunction in neurodegenerative models, with implications for understanding the clinical progression of movement disorders.
A major 2024 review provides comprehensive coverage of ferroptosis as a regulated form of cell death, emphasizing the balance between iron and redox homeostasis[@ferroptosis2024]. The metabolic underpinnings of ferroptosis and its physiological and pathological roles are discussed, with particular attention to implications for neurodegenerative diseases.
The identification of quercetin as an inhibitor of neuronal pyroptosis and ferroptosis through modulation of microglial M1/M2 polarization represents a promising therapeutic approach[@quercetin2024]. This natural compound demonstrates how targeting neuroinflammation can indirectly modulate iron-dependent cell death pathways.